📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
TruAlt Bioenergy Q3 FY26 Revenue Jumps 70% to ₹731 Cr; EBITDA Up 7.5%
TruAlt Bioenergy reported a robust 69.75% YoY growth in total income to ₹730.86 crore for Q3 FY26, driven by the commissioning of grain-based integration and expanded plant operations. While EBITDA grew 7.54% to ₹134 crore, PAT saw a slight decline of 7.98% to ₹69.19 crore due to transitional operating factors. The company has achieved full operational status for all five ethanol plants, positioning it for near year-round production. Strategic expansions are underway in Compressed Biogas (CBG) with 24 planned units and a 100 million litre Sustainable Aviation Fuel (SAF) project.
Key Highlights
Total income increased 69.75% YoY to ₹730.86 crore in Q3 FY26.
EBITDA rose to ₹134.00 crore, though consolidated EBITDA margins compressed to 18.79% from 30.02% YoY.
Ethanol production capacity stabilized at 5.5 to 6 crore litres per month with all 5 units now operational.
CBG segment recorded 63% EBITDA margins for 9M FY26 with plans for 24 greenfield units via JVs with GAIL and Sumitomo.
Progressing on a 100 million litres per annum SAF facility in Andhra Pradesh with Honeywell UOP technology.
👀 What to Watch
Investors should focus on the company's ability to restore margins as it moves past the 'transitional' phase into full-scale operations. The aggressive diversification into CBG and SAF offers significant long-term growth potential, but execution of the JV projects remains the primary monitorable.
TruAlt Bioenergy 9M FY26 Income Rises 13% to ₹1,187 Cr; Ethanol Capacity Hits 2,000 KLPD
TruAlt Bioenergy reported a 13.28% YoY growth in consolidated total income to ₹1,187.05 crore for the nine months ended December 31, 2025. While EBITDA grew by 10% to ₹170.99 crore, PBT saw a marginal decline of 4.72% due to higher finance costs and depreciation following the commissioning of new grain-based capacities. The company has successfully transitioned to a year-round multi-feed platform, achieving a monthly revenue run rate of ₹350-400 crore in its ethanol segment.
Key Highlights
Consolidated 9M FY26 Total Income reached ₹1,187.05 Cr with a PAT of ₹35.92 Cr.
Ethanol capacity reached 2,000 KLPD with 65% dual-feed integration, enabling near year-round operations.
CBG segment demonstrated high profitability with an EBITDA margin of 63% and PAT margin of 43% for 9M FY26.
Proposed ₹2,250 Cr investment in a 100 million liters/annum Sustainable Aviation Fuel (SAF) facility in Andhra Pradesh.
Retail fuel network expanded to 7 operational outlets with a target to scale to 75 outlets in FY27.
👀 What to Watch
Investors should focus on the company's transition from a seasonal to a year-round producer and the high-margin potential of its CBG and upcoming SAF segments. Monitor the stabilization of finance costs as the recent capital expenditure begins to reflect fully in the bottom line.
TruAlt Bioenergy Q3 FY26 Revenue Surges 72% YoY to ₹713 Cr; Net Profit at ₹69 Cr
TruAlt Bioenergy reported a robust 71.8% year-on-year growth in consolidated revenue, reaching ₹71,323.75 lakhs for the quarter ended December 31, 2025. Despite the revenue jump, net profit saw a slight decline of 8% to ₹6,918.95 lakhs compared to ₹7,519.22 lakhs in the same period last year, primarily due to higher finance costs and operational seasonality. This marks the company's first full quarter of reporting since its listing in October 2025. The company also progressed on its Joint Venture with Sumitomo Corporation and is awaiting regulatory clearance for its Unit 5 facility.
Key Highlights
Consolidated Revenue from Operations increased to ₹71,323.75 lakhs from ₹41,511.40 lakhs YoY.
Net Profit for Q3 FY26 stood at ₹6,918.95 lakhs with an EPS of ₹8.07.
Utilized ₹51,937 lakhs of the ₹75,000 lakhs IPO proceeds for capex and working capital.
Executed a Joint Venture agreement with Sumitomo Corporation for a 49% stake in TruAlt Gas Private Limited.
Unit 5 remains non-operational pending 'Consent to Operate' (CTO) from regulatory authorities.
👀 What to Watch
Investors should monitor the timeline for Unit 5's operational clearance and the impact of dual-feed conversions on future margins. While top-line growth is strong, the slight dip in profitability and high finance costs warrant a cautious but observant approach.
TruAlt Bioenergy Q3 FY26 PAT at ₹69.19 Cr; Revenue Surges to ₹713.24 Cr Post-Listing
TruAlt Bioenergy reported a significant turnaround in Q3 FY26, posting a consolidated net profit of ₹69.19 crore compared to a loss of ₹37.94 crore in the previous quarter. Revenue from operations surged to ₹713.24 crore as the company moved out of the seasonal off-period and Unit 1 resumed operations in November 2025. The company successfully utilized ₹519.37 crore of its ₹750 crore IPO proceeds towards capex and working capital. Furthermore, a strategic Joint Venture agreement was executed with Sumitomo Corporation for its gas subsidiary.
Key Highlights
Consolidated Revenue from Operations grew to ₹713.24 crore in Q3 FY26 from ₹114.86 crore in Q2 FY26.
Net Profit for the quarter stood at ₹69.19 crore, rebounding from a sequential loss of ₹37.94 crore.
IPO proceeds of ₹519.37 crore utilized out of ₹750 crore, with ₹140.13 crore spent on capital expenditure.
Executed JV agreement with Sumitomo Corporation for a 49% equity interest in TruAlt Gas Private Limited.
Unit 1 became operational in November 2025 following dual-feed capability conversion; Units 2, 4, and 5 are yet to reach normalized levels.
👀 What to Watch
The sharp sequential recovery in earnings and efficient utilization of IPO funds are positive indicators for this newly listed entity. Investors should monitor the operationalization of Unit 5 and the progress of dual-feed conversions at other units to gauge full-year earning potential.
